Business Travel News has named Moderna's Steinke as its Travel Manager of the Year, one of the most closely watched individual honors in corporate travel.

The award places a spotlight on the biotechnology company's travel program at a moment when pharma and life sciences travel budgets remain among the most resilient in managed travel. Moderna's rise to global prominence during the pandemic transformed it from a relatively small developer into a company with an international footprint — and with it, a travel program that has had to scale quickly across clinical, commercial and manufacturing travel needs.

BTN's annual recognition typically goes to travel managers whose programs demonstrate measurable results in areas that matter directly to sellers of travel: supplier negotiation outcomes, compliance and adoption rates, data-driven sourcing decisions, and the ability to reshape distribution relationships under pressure. Suppliers and TMCs tracking the honor often treat it as a signal of which buyer programs will set the standard for the coming RFP cycle.

For travel sellers, the significance is practical. Award-winning programs tend to influence peer benchmarks — negotiated rate structures, booking-tool mandates, sustainability requirements and duty-of-care expectations that ripple through corporate travel distribution. A pharma buyer of Moderna's profile also carries weight in premium-cabin airline contracts and hotel programs tied to clinical trial sites and conference activity.

The recognition comes as corporate travel managers across sectors push for tighter data integration, direct connectivity with suppliers, and greater control over content distribution — pressures that airlines, hotel chains and technology intermediaries have all had to answer in recent contracting rounds.

How Steinke's program evolves in the year ahead, and whether its practices spread across the life sciences buyer segment, will be a benchmark worth watching through the next negotiation season.